The newly identified coronavirus, SARS-CoV-2 (2019-nCoV), led to pneumonia (COVID-19). SARS-CoV-2 belongs to the genus of beta coronaviruses, which also includes the SARS CoV (2003) and the MERS CoV (2012). Like all other coronaviruses, the SARS-CoV-2 genome (2019-nCoV) codes for the spike protein, envelope protein, membrane protein and nucleocapsid protein.

The immune response pattern against CoV-2-SARS is as follows. IgM antibody levels begin to rise about a week after the initial infection, while IgG antibodies appear later than IgM antibodies (usually within 14 days of infection) and may last 6 months to several years, which means that IgG antibodies serve as an indicator of a previous infection. Patients who are infected with SARS-CoV-2 can be quickly identified by simultaneous IgM and IgG monitoring. IgA appears earlier than IgG and may sometimes help with diagnosis in the early phase of the disease.

Our ELISA kits can detect IgM and/or IgG directed against SARS-CoV-2 antigens.